Cathepsin S: a double-edged protease in barrier damage, neuroimmune inflammation, and tissue repair, with implications for dermatology
- 1Department of Dermatology, The Seventh People’s Hospital of Shenyang
- 2Department of Gastroenterology, The People’s Hospital of Liaoning Province
Abstract
Cathepsin S (CTSS) is a lysosomal cysteine protease traditionally recognized for its role in invariant-chain degradation and major histocompatibility complex class II antigen presentation. However, unlike many lysosomal cathepsins, CTSS remains active at neutral or mildly acidic pH, enabling proteolytic functions at the cell surface and within extracellular inflammatory microenvironments. This property makes CTSS particularly relevant to skin biology, where barrier disruption, immune activation, neuroimmune signaling, extracellular matrix remodeling, angiogenesis, fibrosis, tumor progression, and tissue repair often coexist. This review summarizes the context-dependent and double-edged role of CTSS in inflammation and repair, with emphasis on its dermatological relevance. CTSS can promote pathogenic inflammation through multiple mechanisms, including regulation of antigen presentation, activation of cytokine pathways such as IL-36γ, degradation of antimicrobial and barrier-associated proteins, activation of protease-activated receptor 2, cleavage of fractalkine/CX3CL1, and modulation of neuroimmune circuits involved in itch and pain. These mechanisms implicate CTSS in inflammatory and immune-mediated dermatoses such as psoriasis, atopic dermatitis, vitiligo, rosacea, seborrheic dermatitis, and cutaneous lupus-related autoimmunity. CTSS may also contribute to extracellular matrix turnover, fibroblast activation, vascular remodeling, skin aging, keloid formation, systemic sclerosis-associated fibrosis, and cutaneous melanoma progression. Conversely, CTSS is not uniformly pathogenic. In selected contexts, it may support macrophage, M2 polarization, matrix remodeling, wound repair, and inflammatory resolution. This duality suggests that the biological impact of CTSS depends on its timing, location, cellular source, substrate specificity, and disease stage. Recent pharmacological findings, including rebound CTSS activity and increased CTSS protein mass after repeated administration of a selective CTSS inhibitor, further indicate that simple systemic inhibition may be insufficient or potentially counterproductive. Therefore, CTSS should be viewed as a context-dependent protease switch rather than a universally harmful enzyme. A better understanding of its compartment-specific and stage-specific functions may help guide more selective therapeutic strategies, including local delivery, substrate-selective modulation, combination approaches, and disease-stage-adapted intervention. This framework may refine the development of CTSS-targeted therapies for skin diseases and skin-related immune disorders.
Related
- A mouse neuroimmune circuit that regulates allergic inflammation in the esophagus
- Gut Microbiota-Driven Neuroimmune Crosstalk in Ulcerative Colitis: From Mechanisms to Therapeutic Implications
- From respiratory viral infection to persistent cough hypersensitivity: neuroimmune regulation and therapeutic implications of P2X3/TRP ion-channel targets
- Mechanisms of neuroimmune crosstalk in vestibular disorders: Linking inflammation with neural circuit dysfunction (Review)
- A neuroimmune hypothesis linking chronic cervical inflammation to systemic symptoms: the role of the vagus–NTS axis
BibTeX
@article{wu2026cathepsin,
title = {{Cathepsin S: a double-edged protease in barrier damage, neuroimmune inflammation, and tissue repair, with implications for dermatology}},
author = {Haien Wu and Fang Su and Chang Li and Chunfang Guo and Zhen Wang},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1937685},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1937685/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Cathepsin S: a double-edged protease in barrier damage, neuroimmune inflammation, and tissue repair, with implications for dermatology
AU - Haien Wu
AU - Fang Su
AU - Chang Li
AU - Chunfang Guo
AU - Zhen Wang
PY - 2026
DA - 2026/10/05
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1937685
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1937685/full
AB - Cathepsin S (CTSS) is a lysosomal cysteine protease traditionally recognized for its role in invariant-chain degradation and major histocompatibility complex class II antigen presentation. However, unlike many lysosomal cathepsins, CTSS remains active at neutral or mildly acidic pH, enabling proteolytic functions at the cell surface and within extracellular inflammatory microenvironments. This property makes CTSS particularly relevant to skin biology, where barrier disruption, immune activation, neuroimmune signaling, extracellular matrix remodeling, angiogenesis, fibrosis, tumor progression, and tissue repair often coexist. This review summarizes the context-dependent and double-edged role of CTSS in inflammation and repair, with emphasis on its dermatological relevance. CTSS can promote pathogenic inflammation through multiple mechanisms, including regulation of antigen presentation, activation of cytokine pathways such as IL-36γ, degradation of antimicrobial and barrier-associated proteins, activation of protease-activated receptor 2, cleavage of fractalkine/CX3CL1, and modulation of neuroimmune circuits involved in itch and pain. These mechanisms implicate CTSS in inflammatory and immune-mediated dermatoses such as psoriasis, atopic dermatitis, vitiligo, rosacea, seborrheic dermatitis, and cutaneous lupus-related autoimmunity. CTSS may also contribute to extracellular matrix turnover, fibroblast activation, vascular remodeling, skin aging, keloid formation, systemic sclerosis-associated fibrosis, and cutaneous melanoma progression. Conversely, CTSS is not uniformly pathogenic. In selected contexts, it may support macrophage, M2 polarization, matrix remodeling, wound repair, and inflammatory resolution. This duality suggests that the biological impact of CTSS depends on its timing, location, cellular source, substrate specificity, and disease stage. Recent pharmacological findings, including rebound CTSS activity and increased CTSS protein mass after repeated administration of a selective CTSS inhibitor, further indicate that simple systemic inhibition may be insufficient or potentially counterproductive. Therefore, CTSS should be viewed as a context-dependent protease switch rather than a universally harmful enzyme. A better understanding of its compartment-specific and stage-specific functions may help guide more selective therapeutic strategies, including local delivery, substrate-selective modulation, combination approaches, and disease-stage-adapted intervention. This framework may refine the development of CTSS-targeted therapies for skin diseases and skin-related immune disorders.
SN - 1664-3224
ER -